Table 7.
Clinical outcomes for patients with treatment compliant to NCCS guidelines stratified by the HKLC system
| HKLC stage | Status | Median OS (95% CI) | p value | Median PFS (95% CI) | p value |
|---|---|---|---|---|---|
| Stage 1 (N = 123) | Compliant (N = 123) | 61.31 (ne, ne) | − | ne | − |
| Stage 2 (N = 61) | Noncompliant (N = 10) Compliant (N = 51) |
36.67 (10.19, 38.60) 40.94 (25.43, ne) |
0.3289 | 10.32 (5.49, 22.67) 9.89 (6.57, 16.69) |
0.8336 |
| Stage 3 (N = 100) | Noncompliant (N = 17) | 9.36 (4.86, 23.23) | 0.0844 | 9.07 (3.71, 21.52) | 0.5271 |
| Compliant (N = 83) | 22.83 (13.11, ne) | 7.43 (4.44, 10.02) | |||
| Stage 4 (N = 138) | Noncompliant (N = 4) | 21.88 (11.83, ne) | 0.1232 | 7.13 (3.61, 7.20) | 0.2931 |
| Compliant (N = 134) | 8.57 (7.40, 11.17) | 4.14 (3.39, 5.59) | |||
| Stage 5 (N = 36) | Noncompliant (N = 14) Compliant (N = 22) |
4.67 (1.64, 5.52) 2.66 (1.48, 4.50) |
0.2285 | 12.29 (1.58, 12.29) ne |
0.3298 |
ne, not estimable; HKLC, Hong Kong Liver Cancer; CI, confidence interval; NCCS, National Cancer Centre Singapore.